Company profile

Lysogene is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 products in development phase for the treatment of Sanfilippo syndrom and gangliosidosis.

Source: Cofisem - Last Update: 01 Aug 2019
Key Executives
Chief Executive Officer Karen Aiach
Administrative & Finance Director Dominique Martin
Source: Cofisem - Last Update: 01 Aug 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales 3,590 0 0
Income from ordinary activities 3,590 0 1,375 344 515
Operating income -10,955 -17,216 -7,289 -3,855 -639
Cost (net) of financial indebtedness -1
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -10,925 -17,794 -7,484 -3,757 -630
Net income (Group share) -10,925 -17,794 -7,484 -3,757 -630
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 01 Aug 2019
Shareholder information
Flottant 29.09 %
Sofinnova Capital VII 26.21 %
Innobio 12.30 %
Novo 12.30 %
KGA SAS 9.23 %
Sarepta Therapeutics 7.01 %
Karen Aiach 2.60 %
Employees 1.26 %
Source: Cofisem - Last Update: 20 May 2019

Address

Lysogene

18-20 Rue Jacques Dulud
FR-92200 Neuilly-sur-Seine
France
Source: Cofisem - Last Update: 01 Aug 2019

Contact

Sarah Ankri
Source: Cofisem - Last Update: 01 Aug 2019